Publications:

---

Proteostasis, oxidative stress and aging.

Redox Biology

Korovila, Ioanna I; Hugo, Martín M; Castro, José Pedro JP; Weber, Daniela D; Höhn, Annika A; Grune, Tilman T; Jung, Tobias T

Publication Date: 2017-10

Variant appearance in text: PI3K: i20S

PubMed Link: 28763764

Variant Present in the following documents:

• Main text
• main.pdf

View BVdb publication page

---

Carfilzomib boosted combination therapy for relapsed multiple myeloma.

Oncotargets And Therapy

Steiner, Raphael E RE; Manasanch, Elisabet E EE

Publication Date: 2017

Variant appearance in text: PI3K: i20S

PubMed Link: 28243125

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Redox control of protein degradation.

Redox Biology

Pajares, Marta M; Jiménez-Moreno, Natalia N; Dias, Irundika H K IHK; Debelec, Bilge B; Vucetic, Milica M; Fladmark, Kari E KE; Basaga, Huveyda H; Ribaric, Samo S; Milisav, Irina I; Cuadrado, Antonio A

Publication Date: 2015-12

Variant appearance in text: PI3K: i20S

PubMed Link: 26381917

Variant Present in the following documents:

• main.pdf

View BVdb publication page

---

Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.

Journal Of Cellular And Molecular Medicine

Kubiczkova, Lenka L; Pour, Ludek L; Sedlarikova, Lenka L; Hajek, Roman R; Sevcikova, Sabina S

Publication Date: 2014-06

Variant appearance in text: PI3K: i20S

PubMed Link: 24712303

Variant Present in the following documents:

• Main text
• jcmm0018-0947.pdf

View BVdb publication page

---

Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models.

Oncogenesis

Crawford, L J LJ; Chan, E T ET; Aujay, M M; Holyoake, T L TL; Melo, J V JV; Jorgensen, H G HG; Suresh, S S; Walker, B B; Irvine, A E AE

Publication Date: 2014-03-03

Variant appearance in text: PI3K: i20S

PubMed Link: 24590311

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Novel treatment options for Waldenström macroglobulinemia.

Clinical Lymphoma, Myeloma & Leukemia

Leblebjian, Houry H; Agarwal, Amit A; Ghobrial, Irene I

Publication Date: 2013-09

Variant appearance in text: PI3K: i20S

PubMed Link: 24290218

Variant Present in the following documents:

• Main text

View BVdb publication page

---

The resistance mechanisms of proteasome inhibitor bortezomib.

Biomarker Research

Lü, Shuqing S; Wang, Jianmin J

Publication Date: 2013-03-01

Variant appearance in text: PI3K: i20S

PubMed Link: 24252210

Variant Present in the following documents:

• Main text
• 2050-7771-1-13.pdf

View BVdb publication page

---

The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells.

Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research

Gupta, Sneha V SV; Hertlein, Erin E; Lu, Yanhui Y; Sass, Ellen J EJ; Lapalombella, Rosa R; Chen, Timothy L TL; Davis, Melanie E ME; Woyach, Jennifer A JA; Lehman, Amy A; Jarjoura, David D; Byrd, John C JC; Lucas, David M DM

Publication Date: 2013-05-01

Variant appearance in text: PI3K: i20S

PubMed Link: 23515408

Variant Present in the following documents:

• Main text

View BVdb publication page

---